Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy. Results of a multicenter, international, clinical investigation

Thomas C. Abshire, H. H. Brackmann, I. Scharrer, K. Hoots, C. Gazengel, Jerry S Powell, E. Gorina, E. Kellermann, E. Vosburgh

Research output: Contribution to journalArticle

110 Citations (Scopus)

Abstract

To add an increased level of safety to antihemophilic factor replacement therapy, a full-length, recombinant Factor VIII (rFVIII) product has been developed without human-derived plasma proteins during purification and formulation and using an additional solvent/detergent viral inactivation step. This first clinical trial of a sucrose-formulated full-length rFVIII (rFVIII-FS) was conducted in previously treated patients (≥ 100 prior exposure days) with severe (< 2% FVIII) hemophilia A in North America (NA) and Europe (EU). Pharmacokinetic profiles for rFVIII-FS were compared with those of currently licensed rFVIII product (Kogenate®) in 35 patients. Safety and efficacy during home therapy were evaluated in 71 patients. The new formulation displayed a pharmacokinetic profile similar to that of rFVIII. Patients on home therapy received a cumulative total of 11,867 exposure days, 12,546 infusions, and 22,443,694 IU of rFVIII-FS. Of 2585 bleeds, 93.5% were treated with 1-2 infusions and 80.5% of responses were rated as excellent or good. No evidence of de novo inhibitor formation was observed. Only 0.27% of infusions were associated with any drug-related adverse event. Except for an episode of intermittent chest pain with palpitations which ceased after treatment with analgesics, associated adverse events were mild or moderate. Overall, rFVIII-FS provided excellent hemostatic control, was well-tolerated, and caused no significant adverse effects, thus demonstrating safety and efficacy for treatment of bleeds in patients with hemophilia A.

Original languageEnglish (US)
Pages (from-to)811-816
Number of pages6
JournalThrombosis and Haemostasis
Volume83
Issue number6
StatePublished - 2000

Fingerprint

Factor VIII
Hemophilia A
Sucrose
Therapeutics
Safety
Pharmacokinetics
Virus Inactivation
human F8 protein
Hemostatics
North America
Drug-Related Side Effects and Adverse Reactions
Chest Pain
Detergents
Analgesics
Blood Proteins
Clinical Trials

Keywords

  • Full-length rFVIII
  • Hemophilia A
  • Recombinant Factor VIII

ASJC Scopus subject areas

  • Hematology

Cite this

Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy. Results of a multicenter, international, clinical investigation. / Abshire, Thomas C.; Brackmann, H. H.; Scharrer, I.; Hoots, K.; Gazengel, C.; Powell, Jerry S; Gorina, E.; Kellermann, E.; Vosburgh, E.

In: Thrombosis and Haemostasis, Vol. 83, No. 6, 2000, p. 811-816.

Research output: Contribution to journalArticle

Abshire, Thomas C. ; Brackmann, H. H. ; Scharrer, I. ; Hoots, K. ; Gazengel, C. ; Powell, Jerry S ; Gorina, E. ; Kellermann, E. ; Vosburgh, E. / Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy. Results of a multicenter, international, clinical investigation. In: Thrombosis and Haemostasis. 2000 ; Vol. 83, No. 6. pp. 811-816.
@article{cc64045a9cfd43278000c7a4b727fa0c,
title = "Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy. Results of a multicenter, international, clinical investigation",
abstract = "To add an increased level of safety to antihemophilic factor replacement therapy, a full-length, recombinant Factor VIII (rFVIII) product has been developed without human-derived plasma proteins during purification and formulation and using an additional solvent/detergent viral inactivation step. This first clinical trial of a sucrose-formulated full-length rFVIII (rFVIII-FS) was conducted in previously treated patients (≥ 100 prior exposure days) with severe (< 2{\%} FVIII) hemophilia A in North America (NA) and Europe (EU). Pharmacokinetic profiles for rFVIII-FS were compared with those of currently licensed rFVIII product (Kogenate{\circledR}) in 35 patients. Safety and efficacy during home therapy were evaluated in 71 patients. The new formulation displayed a pharmacokinetic profile similar to that of rFVIII. Patients on home therapy received a cumulative total of 11,867 exposure days, 12,546 infusions, and 22,443,694 IU of rFVIII-FS. Of 2585 bleeds, 93.5{\%} were treated with 1-2 infusions and 80.5{\%} of responses were rated as excellent or good. No evidence of de novo inhibitor formation was observed. Only 0.27{\%} of infusions were associated with any drug-related adverse event. Except for an episode of intermittent chest pain with palpitations which ceased after treatment with analgesics, associated adverse events were mild or moderate. Overall, rFVIII-FS provided excellent hemostatic control, was well-tolerated, and caused no significant adverse effects, thus demonstrating safety and efficacy for treatment of bleeds in patients with hemophilia A.",
keywords = "Full-length rFVIII, Hemophilia A, Recombinant Factor VIII",
author = "Abshire, {Thomas C.} and Brackmann, {H. H.} and I. Scharrer and K. Hoots and C. Gazengel and Powell, {Jerry S} and E. Gorina and E. Kellermann and E. Vosburgh",
year = "2000",
language = "English (US)",
volume = "83",
pages = "811--816",
journal = "Thrombosis and Haemostasis",
issn = "0340-6245",
publisher = "Schattauer GmbH",
number = "6",

}

TY - JOUR

T1 - Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy. Results of a multicenter, international, clinical investigation

AU - Abshire, Thomas C.

AU - Brackmann, H. H.

AU - Scharrer, I.

AU - Hoots, K.

AU - Gazengel, C.

AU - Powell, Jerry S

AU - Gorina, E.

AU - Kellermann, E.

AU - Vosburgh, E.

PY - 2000

Y1 - 2000

N2 - To add an increased level of safety to antihemophilic factor replacement therapy, a full-length, recombinant Factor VIII (rFVIII) product has been developed without human-derived plasma proteins during purification and formulation and using an additional solvent/detergent viral inactivation step. This first clinical trial of a sucrose-formulated full-length rFVIII (rFVIII-FS) was conducted in previously treated patients (≥ 100 prior exposure days) with severe (< 2% FVIII) hemophilia A in North America (NA) and Europe (EU). Pharmacokinetic profiles for rFVIII-FS were compared with those of currently licensed rFVIII product (Kogenate®) in 35 patients. Safety and efficacy during home therapy were evaluated in 71 patients. The new formulation displayed a pharmacokinetic profile similar to that of rFVIII. Patients on home therapy received a cumulative total of 11,867 exposure days, 12,546 infusions, and 22,443,694 IU of rFVIII-FS. Of 2585 bleeds, 93.5% were treated with 1-2 infusions and 80.5% of responses were rated as excellent or good. No evidence of de novo inhibitor formation was observed. Only 0.27% of infusions were associated with any drug-related adverse event. Except for an episode of intermittent chest pain with palpitations which ceased after treatment with analgesics, associated adverse events were mild or moderate. Overall, rFVIII-FS provided excellent hemostatic control, was well-tolerated, and caused no significant adverse effects, thus demonstrating safety and efficacy for treatment of bleeds in patients with hemophilia A.

AB - To add an increased level of safety to antihemophilic factor replacement therapy, a full-length, recombinant Factor VIII (rFVIII) product has been developed without human-derived plasma proteins during purification and formulation and using an additional solvent/detergent viral inactivation step. This first clinical trial of a sucrose-formulated full-length rFVIII (rFVIII-FS) was conducted in previously treated patients (≥ 100 prior exposure days) with severe (< 2% FVIII) hemophilia A in North America (NA) and Europe (EU). Pharmacokinetic profiles for rFVIII-FS were compared with those of currently licensed rFVIII product (Kogenate®) in 35 patients. Safety and efficacy during home therapy were evaluated in 71 patients. The new formulation displayed a pharmacokinetic profile similar to that of rFVIII. Patients on home therapy received a cumulative total of 11,867 exposure days, 12,546 infusions, and 22,443,694 IU of rFVIII-FS. Of 2585 bleeds, 93.5% were treated with 1-2 infusions and 80.5% of responses were rated as excellent or good. No evidence of de novo inhibitor formation was observed. Only 0.27% of infusions were associated with any drug-related adverse event. Except for an episode of intermittent chest pain with palpitations which ceased after treatment with analgesics, associated adverse events were mild or moderate. Overall, rFVIII-FS provided excellent hemostatic control, was well-tolerated, and caused no significant adverse effects, thus demonstrating safety and efficacy for treatment of bleeds in patients with hemophilia A.

KW - Full-length rFVIII

KW - Hemophilia A

KW - Recombinant Factor VIII

UR - http://www.scopus.com/inward/record.url?scp=0034045817&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034045817&partnerID=8YFLogxK

M3 - Article

VL - 83

SP - 811

EP - 816

JO - Thrombosis and Haemostasis

JF - Thrombosis and Haemostasis

SN - 0340-6245

IS - 6

ER -